Clinical Trials
120 trialsPazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors
National Cancer Institute (NCI)
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
M.D. Anderson Cancer Center
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
MOST plus
Centre Leon Berard
A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma
Imbioray (Hangzhou) Biomedicine Co., Ltd.
Pazopanib With or Without Pembrolizumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Mayo Clinic
Evaluation of the Efficacy and Safety of Pazopanib in Combination with TGI/CIV for Recurrent or Refractory Rhabdomyosarcoma in Children or Adolescents
Shandong Cancer Hospital and Institute
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion
Tianjin Medical University Second Hospital
PazoDoble
North Eastern German Society of Gynaecological Oncology
Pazopanib Maintenance Phase II
Ludwig-Maximilians - University of Munich
A Study of Vascular Endothelial Growth Factor (VEGF) Inhibition in Patients With Unilateral Upper Extremity Lymphedema Following Treatment for Cancer
Indiana University
TAPAZ
ARCAGY/ GINECO GROUP
IO-PAZ
Novartis
A Study of Pazopanib and Durvalumab for Metastatic Soft Tissue Sarcoma
Yonsei University
Trial of Pazopanib in Patients With Solitary Fibrous Tumor and Extraskeletal Myxoid Chondrosarcoma
Grupo Espanol de Investigacion en Sarcomas
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
Emerald Clinical Inc.
Pazopanib Hydrochloride in Treating Patients With Advanced Angiosarcoma
Fox Chase Cancer Center
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
City of Hope Medical Center
Trebananib With or Without Bevacizumab, Pazopanib Hydrochloride, Sorafenib Tosylate, or Sunitinib Malate in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas
Northwestern University
Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery
Academic and Community Cancer Research United
EVA
Heidelberg University
Second-line Pazopanib Renal Cell Carcinoma (RCC) Study. CTRIAL-IE (ICORG) 10-01, V5
Cancer Trials Ireland
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
NIVOSWITCH
AIO-Studien-gGmbH
Pazotest-01
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
BIONIKK
Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung
Emerald Clinical Inc.
PAZOPANIB-AML
University Hospital Muenster
A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
University of Virginia
NOPASS
Heidelberg University
Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors
Novartis
Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy
Washington University School of Medicine
Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial
Grupo Espanol de Investigacion en Sarcomas
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
Washington University School of Medicine
PIPELINE
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Reversing Hormone Resistance in Advanced Breast Cancer With Pazopanib
University of California, San Francisco
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
Lumos Pharma
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
National Cancer Institute (NCI)
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
HYPAZ
Cambridge University Hospitals NHS Foundation Trust
LMS03
UNICANCER
PACSA-ORL02
UNICANCER
FARETES
Kidney Cancer Research Bureau